Temasek-backed Pavilion Capital backs funding in AI biopharma firm Insilico Mars Woo June 12, 2018 PremiumPavilion Capital, a subsidiary of Singapore’s Temasek Holdings, has participated in the latest strategic funding round in US-headquartered artificial intelligence biopharma company Insilico Medicine. The funding amount was not disclosed. Continue reading this story with a subscription to DealStreetAsia. Subscribe Already a subscriber? Log in Should your colleagues be reading this article too? Contact us for corporate subscriptions at firstname.lastname@example.org.